| scholarly article | Q13442814 |
| P50 | author | Ian Harrison | Q57004686 |
| P2093 | author name string | David T Dexter | |
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 34-52 | |
| P577 | publication date | 2013-05-24 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? | |
| P478 | volume | 140 |
| Q39732144 | A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease |
| Q38766912 | A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease. |
| Q38860456 | ALS and FTD: an epigenetic perspective |
| Q92339420 | Acupuncture protects from 6-OHDA-induced neuronal damage by balancing the ratio of DMT1/Fpn1 |
| Q64118812 | Alcohol Extracts From Delay the Progress of Alzheimer's Disease by Regulating DNA Methylation in Rodents |
| Q36587423 | Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate |
| Q41953858 | Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age. |
| Q48466082 | Characterization of brain cell nuclei with decondensed chromatin |
| Q90218966 | Chemical Genetics Screen Identifies Epigenetic Mechanisms Involved in Dopaminergic and Noradrenergic Neurogenesis in Zebrafish |
| Q55065124 | Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury. |
| Q48635091 | Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult |
| Q34667486 | Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra |
| Q41997892 | Comprehensive profiling of lysine acetylation suggests the widespread function is regulated by protein acetylation in the silkworm, Bombyx mori |
| Q26774368 | Computational Modelling Approaches on Epigenetic Factors in Neurodegenerative and Autoimmune Diseases and Their Mechanistic Analysis |
| Q33603777 | Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology |
| Q35820242 | Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study |
| Q39264615 | Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA. |
| Q30432845 | Drug delivery systems, CNS protection, and the blood brain barrier |
| Q89584480 | Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease |
| Q26772307 | Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models |
| Q38742951 | Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases |
| Q38743021 | Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. |
| Q37237028 | Epigenetic findings in autism: new perspectives for therapy |
| Q38379396 | Epigenetic mechanisms in neurological and neurodegenerative diseases |
| Q26770705 | Epigenetics and Triplet-Repeat Neurological Diseases |
| Q27010153 | Epigenetics of Alzheimer's disease and frontotemporal dementia |
| Q28088320 | GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease |
| Q90403568 | Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling |
| Q36563651 | General Base-General Acid Catalysis in Human Histone Deacetylase 8. |
| Q61813466 | HADC8 Inhibitor WK2-16 Therapeutically Targets Lipopolysaccharide-Induced Mouse Model of Neuroinflammation and Microglial Activation |
| Q94544744 | Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation |
| Q35632155 | Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitro |
| Q48458054 | Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice |
| Q93049244 | Implications of Diet and The Gut Microbiome in Neuroinflammatory and Neurodegenerative Diseases |
| Q98564749 | Inhibition of HDAC increases BDNF expression and promotes neuronal rewiring and functional recovery after brain injury |
| Q50662543 | Inhibition of histone deacetylase in the basolateral amygdala facilitates morphine context-associated memory formation in rats. |
| Q38215303 | Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors |
| Q36971583 | Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities |
| Q97882637 | Lipid Metabolism is the common pathologic mechanism between Type 2 Diabetes Mellitus and Parkinson's disease |
| Q91787325 | Mechanism of methylation and acetylation of high GDNF transcription in glioma cells: A review |
| Q91174606 | Metabolomics signatures of acutely ill and short-term weight recovered women with anorexia nervosa |
| Q33821872 | Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests |
| Q47290734 | Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes. |
| Q43067393 | Neuroprotective role of thymoquinone against 1-methyl-4-phenylpyridinium-induced dopaminergic cell death in primary mesencephalic cell culture |
| Q35978159 | Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. |
| Q28080679 | New Insights for Oxidative Stress and Diabetes Mellitus |
| Q92237519 | On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson's Disease |
| Q47259835 | Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. |
| Q22255525 | Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondii |
| Q36574016 | Regulation of Histone Acetylation by Autophagy in Parkinson Disease |
| Q56381130 | Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinson's Disease Data |
| Q50498125 | Sodium butyrate modulates a methamphetamine-induced conditioned place preference. |
| Q43650001 | Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways |
| Q48324385 | Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease |
| Q38361065 | Targeting histone deacetylases: a novel approach in Parkinson's disease |
| Q36077200 | The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats. |
| Q37548331 | The Epigenome as a therapeutic target for Parkinson's disease. |
| Q38940509 | The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. |
| Q58779768 | The etiological changes of acetylation in peripheral nerve injury-induced neuropathic hypersensitivity |
| Q34652493 | The gut microbiome and the brain |
| Q64859138 | The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease |
| Q34429848 | The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals. |
| Q38234971 | The potential of epigenetic therapies in neurodegenerative diseases |
| Q35631468 | Therapeutic perspectives of epigenetically active nutrients. |
| Q92350333 | Trained Innate Immunity Not Always Amicable |
| Q64864775 | Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation. |
| Q48539090 | What is the potential of epigenetics in drug development? |
Search more.